OriGene Technologies, Inc. to Build the World's Largest TrueMAB(TM) Monoclonal Antibody Facility in Wuxi, China

ROCKVILLE, Md., May 18 /PRNewswire/ -- OriGene Technologies, Inc. with the support of Wuxi Biopharmaceutical R&D Outsourcing Services Park (China), will build one of the largest and most sophisticated monoclonal antibody production centers in the world in Wuxi, China. The new, high-throughput production facility is expected to have over one thousand employees with the capacity to produce over 20,000 TrueMAB™ antibodies per year.

Monoclonal antibodies have become an invaluable tool for researchers to develop diagnostic and therapeutic applications. TrueMAB™ antibodies from OriGene are generated using OriGene's large collection of full-length human proteins as primary antigens that have been affinity purified under native conditions to preserve natural protein conformations. As a result, TrueMAB™ antibodies provide higher sensitivity and specificity for the recognition of native epitopes on the protein's natural conformational structures. With the introduction of OriGene's TrueMAB™ antibodies, OriGene now provides higher quality and greater numbers of monoclonal antibodies to the global research market place to address complex applications such as flow cytometry, ELISA, IHC, antibody arrays, Luminex assays and more.

To learn more about OriGene's genome-wide monoclonal antibody program and the TrueMAB™ collection, please visit www.origene.com/antibody/TrueMAB or contact James Hu at [email protected].

About OriGene Technologies

OriGene Technologies, Inc., is a gene centric life sciences company dedicated to support academic, pharmaceutical and biotech companies in their research of gene functions and drug discovery. OriGene develops proteins, antibodies, and other molecular tools to allow researchers to analyze their data on a multiplex level. OriGene's novel product line includes the world's largest cDNA and shRNA clone collections, over 5,000 purified human proteins, high quality monoclonal antibodies (TrueMAB™), 100,000 highly validated human tissues, and protein microarray products and services. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. For more information visit www.origene.com.

SOURCE OriGene Technologies, Inc.